418 related articles for article (PubMed ID: 26869168)
1. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
2. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
3. Combined test versus logrank/Cox test in 50 randomised trials.
Royston P; Choodari-Oskooei B; Parmar MKB; Rogers JK
Trials; 2019 Mar; 20(1):172. PubMed ID: 30885277
[TBL] [Abstract][Full Text] [Related]
4. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
5. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
6. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
7. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
8. Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.
Lachin JM
Stat Med; 2013 Nov; 32(25):4413-25. PubMed ID: 23670965
[TBL] [Abstract][Full Text] [Related]
9. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
Royston P; Parmar MK
BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
[TBL] [Abstract][Full Text] [Related]
10. Sample size calculation for the augmented logrank test in randomized clinical trials.
Hattori S; Komukai S; Friede T
Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
[TBL] [Abstract][Full Text] [Related]
11. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
13. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
[TBL] [Abstract][Full Text] [Related]
14. A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
Yang S; Ambrosius WT; Fine LJ; Bress AP; Cushman WC; Raj DS; Rehman S; Tamariz L
Clin Trials; 2018 Jun; 15(3):305-312. PubMed ID: 29671345
[TBL] [Abstract][Full Text] [Related]
15. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
16. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
17. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
18. A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome.
Royston P
Stata J; 2017 Apr; 17(2):405-421. PubMed ID: 29445320
[TBL] [Abstract][Full Text] [Related]
19. Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin B; Hu C; Korn EL
Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
[TBL] [Abstract][Full Text] [Related]
20. Restricted mean survival time to estimate an intervention effect in a cluster randomized trial.
Vilain-Abraham FL; Tavernier E; Dantan E; Desmée S; Caille A
Stat Methods Med Res; 2023 Oct; 32(10):2016-2032. PubMed ID: 37559486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
